Avatrombopag vs. Placebo for CIT in GI Malignancies

Summary

The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. The names of the study drugs involved in this study are: * Avatrombopag (a thrombopoietin receptor agonist) * Matching placebo

Timeline

Start

2023-11-01

Primary completion

2026-01-02

Completion

2026-07-31

Drugs

Indications